Abstract: The invention provides a dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a methane inhibitor to the animal over a period of time. Preferably the methane inhibitor is a haloform. Also provided is the use of the bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: The present invention provides a composition that can preserve biomaterials. The biomaterial preservation composition of the present invention includes a micro bubble.

Abstract: The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein the dosage form and the bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: The present invention relates to a process for the production of semifluorinated alkanes.

Abstract: A method for cerebral cooling is described using a cooling assembly, which includes first and second elongate tubular members adapted for insertion into a nasal cavity of a patient through the patient's nostrils. The elongate tubular members each have a proximal end, a distal end, a lumen extending therebetween, and a plurality of ports in fluid communication with the lumen. The cooling assembly also includes a manifold and a reservoir, which contains a pressurized fluid that includes a propellant having a boiling point less than 22° C. The elongate tubular members are inserted into the nasal cavity through the patient's nostrils and pressurized fluid is delivered onto a surface of the nasal cavity by infusing the pressurized fluid from the reservoir through the manifold, into the lumens and through the plurality of ports of the first and second elongate tubular members.

Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.

Abstract: Compositions and methods for contraception are disclosed that use 1-bromopropane.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.

Abstract: The invention provides compounds of Formula (I): R1?R2??(I) wherein R1 and R2 have any of the values or specific values defined herein, as well as compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.

Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.

Abstract: A dental curable composition comprises (A) a polymerizable monomer and (B) an organic amine-based polymerization initiator, wherein (A?) a long-chain polymerizable monomer having a chain length of 17 or more atoms is contained in the component (A) and/or (C) a soft resin material are/is contained in the composition, and when the amount (parts by weight) based on 100 parts by weight of the component (A) of the component (A?) is represented by [a?] and the amounts (parts by weight) based on 100 parts by weight of the total of the components (A) and (B) of the components (A), (B) and (C) are represented by (a), (b) and (c), respectively, 70?(a)?99.99, 0.01?(b)?5 30, 1?[a?]/5+(c)/1, 0?[a?]?95, and 0?(c)?250.

Abstract: The present invention provides methods of using halogenated volatile compounds, e.g., halogenated ether, for treating a neurological disorder, e.g., Parkinson's disease.

Abstract: The present invention provides methods for treating inflammation or a wound in a subject in need of such wound treatment or inflammation treatment by delivering a volatile anesthetic to the wound or the inflammation site.

Abstract: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis.

Abstract: Disclosed are diaryl iodonium compositions with antimicrobial activity and low toxicity to plants and mammals. The present diaryl iodonium compositions include a tri-substituted aryl group and a heteroaryl group which produce substantially no chlorobenzene and/or 1,2-dichlorobenzene when applied to microbes.

Abstract: Soil fumigation compositions are provided herein that include methyl iodide, at least one fluorocarbon or hydrofluorocarbon, at least one surfactant, and water. The fumigant can be produced by combining the water and surfactant with an initial mixture that is an azeotropic or azeotrope-like mixture of methyl iodide and at least one fluorocarbon or hydrofluorocarbon. The fumigant compositions can be utilized in drip fumigation processes, and have increased volatility as compared to methyl iodide alone, which can reduce the risk of water contamination when utilizing methyl iodide as a fumigant.

Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Abstract: Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.

Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.

Abstract: Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.

Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.

Abstract: Methods for the use of uncompetitive NMDA receptor antagonist(s) in inhalational anesthesia are provided herein.

Abstract: An azeotropic or azeotrope-like composition comprising a mixture of methyl iodide, 1-chloro-3,3,3,-trifluoropropene, and optionally one or more of fluorocarbons and/or hydrofluorocarbons. The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.

Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.

Abstract: The present invention relates to a series of new chemical agents that demonstrate anti-tumor activity. More particularly, the present invention relates to molecules, referred to as “combi-molecules”, that combine two major mechanisms of anti-tumor action. A combi-molecule is capable of degrading to a ligand involved in cell signaling pathways and to an agent capable of damaging DNA. More specifically, the present invention relates to molecules capable of blocking epidermal growth factor receptor (EGFR) mediated signal transduction and capable of damaging DNA. The present invention also relates to a general method of synthesis of these combi-molecules.

Abstract: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively stimulate bone regeneration and increase osteoblastic activity in a patient.

Abstract: Azeotropic and azeotrope-like compositions of methyl iodide and at least one fluorocarbon or hydrofluorocarbon such as 1,1,1,3,3-pentafluoropropane (HFC-245fa). The compositions are present as a gas, at temperatures of about 30° C. or below. The inventive compositions serve as a non-ozone-depleting gaseous fumigant which is useful in a variety of applications, in place of methyl bromide. These compositions serve as a drop-in replacement for gaseous methyl bromide, providing the benefits of a methyl iodide fumigant while also utilizing existing methyl bromide equipment.

Abstract: The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.

Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.

Abstract: The present invention provides a fumigant for wood parasitic nematodes comprising methyl iodide dissolved in liquefied carbon dioxide, in place of methyl bromide the use of which is globally regulated as ozone depleting substance or a fumigant using methyl iodide dissolved in liquefied carbon dioxide in combination with one or more compounds selected from the group consisting of sulfuryl fluoride, methyl isothiocyanate, phosphine, ethylene oxide, carbonyl sulfide and propylene oxide, and a fumigation method for killing wood parasitic nematodes by using said fumigant.

Abstract: This invention relates to methods of inhibiting a Cav3 calcium channel in a cell using a C2-C10 alkyl alcohol, or mixtures thereof. This invention further relates to methods of treating a thalamocortical dysrhythmia disorder in a mammal and for treating a neurological disorder in a mammal associated with the thalamocortical dysrhythmia using a C2-C10 alkyl alcohol, a lipophilic molecule with a partition coefficient substantially similar to that of a C2-C10 alkyl alcohol, or mixtures thereof, or a pharmaceutical composition comprising the same.

Abstract: Drug delivery models, displays, and systems may be configured to provide a clinician with readily intuitive information about the effects of one or more drugs on a subject. Interactive features may be included to provide a subject-specific model of the expected or predicted effects of one or more drugs on the subject. Additionally, interactive features that effect drug delivery to the subject may also be included. Drug delivery models, displays, and systems may be used in teaching, in advance of treatment, during treatment, or following treatment.

Abstract: Method and article for providing a rapid, broad spectrum bacterial control, and a rapid and persistent antiviral control on an inanimate surface is disclosed. In the method, a compound or composition capable of lowering surface pH to less than about 4 is applied to the surface, and preferably is allowed to remain on the surface, and the nonvolatile components of the composition can form a barrier film or layer on a treated surface.

Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.

Abstract: The present invention relates to stilbene and quinone compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BOC amino acid esters are formed with the phenolic hydroxyl at the 3-position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior art stilbenes.

Abstract: Process for the separation of a mixture comprising at least one hydrofluoroalkane and hydrogen fluoride, according to which a hydrofluoroalkane/hydrogen fluoride mixture is reacted with at least one chlorinated or chlorofluorinated precursor of the hydrofluoroalkane. Process for the preparation of a hydrofluoroalkane comprising such a separation, in combination with a catalytic reaction stage. Azeotropic compositions.

Abstract: The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—RF(CH2)nCR1—CR2—]x, wherein RF is a linear or branched perfluorinated alkyl chain C2F5 to C12F23, R1 and R2 are independently selected from the group consisting of H, CH3, C2H5 and C3H7, n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.

Abstract: The present invention relates to two solvent antimicrobial compositions and methods employing these two solvent compositions. The two solvent compositions typically contain a second solvent that is not or is only sparingly soluble in a diluting solvent. The two solvent composition can form a clear single-phase solution. The two solvent antimicrobial compositions can reduce the population of microbes on various surfaces such as facilities, containers, or equipment found in food, beverage, or pharmaceutical industries at temperatures between about ?70° C. to about 100° C.

Abstract: Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.

Abstract: Carboxylic acid fluorides having a boiling point of preferably less than 100° C. are suitable for use as pesticides. Acetyl fluoride is highly suitable, and Chlorodifluoroacetyl fluoride and trifluoroacetyl fluoride are also very useful. Mixtures of carboxylic acid fluoride pesticides and other pesticides are also disclosed.

Abstract: Disclosed are methods for treating, preventing, or inhibiting diseases and disorders associated with NF-&kgr;B activation including proliferative diseases such as cancer and inflammatory diseases such as pancreatitis in a subject which comprises administering at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species to the subject. Also disclosed are pharmaceutical compositions comprising at least one polyphenolic compound and/or at least one inhibitor of reactive oxygen species. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.

Abstract: Provided is a method of treating a patient having a tissue that is subject to an ischemic event. The method is conducted by parenterally administering a formulation containing a halogenated volatile anesthetic in an amount effective to improve the tissue's resistance to or tolerance of the ischemic event. In preferred embodiment of the invention, the amount of the formulation administered to the patient is sub-anesthetic. The formulation can be administered prior to, concurrently with, or after the ischemic event. The method can be used, for example, for treatment of patients having myocardial or neuronal tissue that is subject to an ischemic event.

Abstract: Compositions and methods for treating a variety of conditions in which a reactive oxygen metabolite (ROM) inhibitor or scavenger is administered alone or in conjunction with additional agents. Such conditions include, cancer, viral diseases, and inflammatory diseases, for example.

Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.

Abstract: Fluorocarbon emulsions comprising a stabilizing, particle size controlling fluorophilic/hydrophilic compound which can have the formula RF1—W—RH1  (I) wherein RF1 is a linear, branched or cyclic C2-14 fluorocarbon group; RH1 is a linear, branched or cyclic C2-18 saturated or unsaturated hydrocarbon group; and W is absent or is a bivalent species chosen from the group consisting of —O—, —S—, or various fluorinated structures. Use of the fluorophilic/lipophilic compound in the dispersions of the invention provides stable particle size and efficient emulsification. The dispersions of the invention can comprise biologically useful additive and can be used for various purposes, as oxygen carriers, contrast agents, or diagnostic agents.

Abstract: The invention concerns semi-fluorinated alkanes of the general formulae RFRH or RFRHRF, RF being a linear or branched perfluoroalkyl group and RH being a linear or branched saturated (hydrocarbon)-alkyl group.

Abstract: Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds by applying a compound comprised of both mono-iodinated hydrocarbons and di-iodinated hydrocarbons. The combination provides an effective insecticide and nemacide along with herbicidal properties without causing significant harm to the ozone layer. Additionally disclosed is a method of soil fumigation comprising applying to a soil an effective amount of a fumigant selected from diiodinated hydrocarbons, polyiodinated hydrocarbons and their combinations.

Abstract: The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.